Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: A systematic review and meta-analysis

Clinics and Research in Hepatology and Gastroenterology

Volumn 39, Issue 1, 2015, Pages 80-92

  Li, Hong ^a   Zhang, Hong min ^a   Chen, Li fen ^a   Chen, Ya qin ^a   Chen, Ling ^a   Ren, Hong ^a,b   Hu, Huai dong ^a,b  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; COCHRANE LIBRARY; EMBASE; HEPATITIS B; HUMAN; LYMPHOMA; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PROPHYLAXIS; SYSTEMATIC REVIEW; VIRUS REACTIVATION; WEB OF SCIENCE;

EID: 84964260866     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2014.07.010     Document Type: Article

References (59)

1. Zhang H., Li H., Yang Y., Li S., Ren H., Zhang D., et al. Differential regulation of host genes including hepatic fatty acid synthase in HBV-transgenic mice. J Proteome Res 2013, 12(6):2967-2979.
2. Alter M.J. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003, 39(Suppl. 1):S64-S69.
3. Ganem D., Prince A.M., Hepatitis B. virus infection-natural history and clinical consequences. N Engl J Med 2004, 350(11):1118-1129.
4. Lok A.S., Liang R.H., Chiu E.K., Wong K.L., Chan T.K., Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991, 100(1):182-188.
5. Nakamura Y., Motokura T., Fujita A., Yamashita T., Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 1996, 78(10):2210-2215.
6. Yeo W., Chan P.K., Zhong S., Ho W.M., Steinberg J.L., Tam J.S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000, 62(3):299-307.
7. Idilman R., Arat M., Soydan E., Toruner M., Soykan I., Akbulut H., et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004, 11(2):141-147.
8. Yeo W., Chan P.K., Hui P., Ho W.M., Lam K.C., Kwan W.H., et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003, 70(4):553-561.
9. Yeo W., Chan P.K., Ho W.M., Zee B., Lam K.C., Lei K.I., et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004, 22(5):927-934.
10. Zhong S., Yeo W., Schroder C., Chan P.K., Wong W.L., Ho W.M., et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004, 11(1):55-59.
11. Fattovich G., Brollo L., Alberti A., Realdi G., Pontisso P., Giustina G., et al. Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis. Liver 1990, 10(3):141-146.
12. Tong M.J., Sampliner R.E., Govindarajan S., Co R.L. Spontaneous reactivation of hepatitis B in Chinese patients with HBsAg-positive chronic active hepatitis. Hepatology 1987, 7(4):713-718.
13. Davis G.L., Hoofnagle J.H. Reactivation of chronic type B hepatitis presenting as acute viral hepatitis. Ann Intern Med 1985, 102(6):762-765.
14. Davis G.L., Hoofnagle J.H., Waggoner J.G. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology 1984, 86(2):230-235.
15. Lai C.L., Chien R.N., Leung N.W., Chang T.T., Guan R., Tai D.I., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998, 339(2):61-68.
16. Jarvis B., Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 1999, 58(1):101-141.
17. Dienstag J.L., Goldin R.D., Heathcote E.J., Hann H.W., Woessner M., Stephenson S.L., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003, 124(1):105-117.
18. de Franchis R., Hadengue A., Lau G., Lavanchy D., Lok A., McIntyre N., et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003, 39(Suppl. 1):S3-S25.
19. Katz L.H., Fraser A., Gafter-Gvili A., Leibovici L., Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008, 15(2):89-102.
20. Lim L.L., Wai C.T., Lee Y.M., Kong H.L., Lim R., Koay E., et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002, 16(11):1939-1944.
21. Haanen J.B., Bieger R., van't Wout J.W. Acute hepatic injury after discontinuation of chemotherapy in a patient with non-Hodgkin's lymphoma and chronic hepatitis B virus infection. Neth J Med 1996, 49(6):239-243.
22. Hoofnagle J.H., Dusheiko G.M., Schafer D.F., Jones E.A., Micetich K.C., Young R.C., et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982, 96(4):447-449.
23. Kumagai K., Takagi T., Nakamura S., Sawada U., Kura Y., Kodama F., et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997, 8(Suppl. 1):107-109.
24. Markovic S., Drozina G., Vovk M., Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999, 46(29):2925-2930.
25. Ziakas P.D., Karsaliakos P., Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009, 94(7):998-1005.
26. Ozguroglu M.A.B., Turna H., Serdengecti S. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-hodgkin's lymphoma. Med Oncol 2004, 21(1):67-72.
27. Chen X.Q., Peng J.W., Lin G.N., Li M., Xia Z.J. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol (Northwood, London, England). 2012, 29(2):1237-1241.
28. Pei S.N., Chen C.H., Lee C.M., Wang M.C., Ma M.C., Hu T.H., et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010, 89(3):255-262.
29. Lim S.T., Fei G., Quek R., Lim L.C., Lee L.H., Yap S.P., et al. The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis. Eur J Haematol 2007, 79(2):132-137.
30. Kim S.J., Hsu C., Song Y.Q., Tay K., Hong X.N., Cao J., Hepatitis B., et al. virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Eur J Cancer (Oxford England: 1990) 2013, 49(16):3486-3496.
31. Shibolet O. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002, 100(2):391-396.
32. Lau G.K., Yiu H.H., Fong D.Y., Cheng H.C., Au W.Y., Lai L.S., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003, 125(6):1742-1749.
33. Li Y.H., He Y.F., Jiang W.Q., Wang F.H., Lin X.B., Zhang L., et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006, 106(6):1320-1325.
34. Higgins J., Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). Cochrane Collab 2011, Available at www.cochrane-handbook.org.
35. Eom C.S., Park S.M., Myung S.K., Yun J.M., Ahn J.S. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med 2011, 9(3):257-267.
36. George K.K., Lau H.H.Y.Y., Daniel Y.T., Fong Hoi-Ching Cheng, Wing-Yan A.U., Lydia S.F., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003, 125:1742-1749.
37. Hsu C., Hsiung C.A., Su I.J., Hwang W.S., Wang M.C., Lin S.F., et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008, 47(3):844-853.
38. Idilman R.M.A., Soydan E., Törü ner M., Soykan I.H.A., Arslan Ö., Özcan M., et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004, 11(2):141-147.
39. Leaw S.J., Yen C.J., Huang W.T., Chen T.Y., Su W.C., Tsao C.J. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004, 83(5):270-275.
40. Gyeong-Won L.M-HR, Jae-Lyun L. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis B surface antigen (HBs Ag)-positive patients with non-hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 2003, 18:849-854.
41. Persico M., De Marino F., Russo G.D., Morante A., Rotoli B., Torella R., et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002, 99(2):724-725.
42. Tsutsumi Y., Shigematsu A., Hashino S., Tanaka J., Chiba K., Masauzi N., et al. Analysis of reactivation of hepatitis B virus in the treatment of B-cell non-Hodgkin's lymphoma in Hokkaido. Ann Hematol 2009, 88(4):375-377.
43. Yeo W., Zee B., Zhong S., Chan P.K., Wong W.L., Ho W.M., et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004, 90(7):1306-1311.
44. Liaw Y.F. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol 1998, 13(1):14-20.
45. Hsu C.H., Hsu H.C., Chen H.L., Gao M., Yeh P.Y., Chen P.J., et al. Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res 2004, 24(5A):3035-3040.
46. Perrillo R.P. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001, 120(4):1009-1022.
47. Liang R., Lau G.K., Kwong Y.L. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999, 17(1):394-398.
48. Liang R.H., Lok A.S., Lai C.L., Chan T.K., Todd D., Chiu E.K., et al. infection in patients with lymphomas. Hematol Oncol 1990, 8(5):261-270.
49. Liao C.A., Lee C.M., Wu H.C., Wang M.C., Lu S.N., Eng H.L. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002, 116(1):166-169.
50. Steinberg J.L., Yeo W., Zhong S., Chan J.Y., Tam J.S., Chan P.K., et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol 2000, 60(3):249-255.
51. Perrillo R.P. Hepatitis B and renal transplantation: securing the sword of damocles. Hepatology 2002, 36(5):1041-1045.
52. Liu J.-Y., Sheng Y.-J., Ding X.-C., Tang H., Tong S.-W., Zhang D.-Z., et al. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis. J Formos Med Assoc 2012, xx:1-10.
53. Lau D.T., Khokhar M.F., Doo E., Ghany M.G., Herion D., Park Y., et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000, 32(4 Pt. 1):828-834.
54. Perez-Roldan F., Gonzalez-Carro P., Villafanez-Garcia M.C. Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N Engl J Med 2005, 352(3):310-311.
55. Watanabe M., Shibuya A., Takada J., Tanaka Y., Okuwaki Y., Minamino T., et al. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med 2010, 21(4):333-337.
56. Wiens A., Lenzi L., Venson R., Pedroso M.L., Correr C.J., Pontarolo R. Economic evaluation of treatments for chronic hepatitis B. Braz J Infect Dis 2013, 17(4):418-426.
57. Felder T.M., Bennett C.L. Can patients afford to be adherent to expensive oral cancer drugs?.: unintended consequences of pharmaceutical development. J Oncol Pract 2013, 9(6S):64s-66s.
58. Wang Y.H., Fan L., Wang L., Zhang R., Xu J., Fang C., et al. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy. Support Care Cancer 2013, 21(5):1265-1271.
59. Xie W., Zhou D., Hu K., Xiao X., Huang W., He J., et al. Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy. Exp Ther Med 2013, 6(1):109-114.